The POU transcription factor OCT4 is a pleiotropic regulator of gene expression in embryonic stem cells. Recent studies demonstrated that OCT4 is aberrantly expressed in multiple types of human cancer; however, the underlying molecular mechanism remains largely unknown. In this study, we report that OCT4-pg4, a pseudogene of OCT4, is abnormally activated in hepatocellular carcinoma (HCC). The expression level of OCT4-pg4 is positively correlated with that of OCT4, and both gene transcripts can be directly targeted by a tumor-suppressive micro RNA miR-145. We find that the non-coding RNA OCT4-pg4 is biologically active, as it can upregulate OCT4 protein level in HCC. Mechanistic analysis revealed that OCT4-pg4 functions as a natural micro RNA sponge to protect OCT4 transcript from being inhibited by miR-145. In addition, our study also showed that OCT4-pg4 can promote growth and tumorigenicity of HCC cells, thus exerting an oncogenic role in hepatocarcinogenesis. Furthermore, survival analysis suggests that high OCT4-pg4 level is significantly correlated with poor prognosis of HCC patients. Taken together, our finding adds a new layer of post-transcriptional regulation of OCT4 and sheds new light on the treatment of human HCC.
Introduction
Hepatocellular carcinoma (HCC) is among the most prevalent and lethal cancers in the human population (1) . It arises from modulation of multiple genes by mutations, epigenetic regulation, non-coding RNAs and post-translational modifications of proteins. Although >40% of HCCs are clonal and thought to arise from cancer stem cells (CSCs), the underlying molecular mechanisms remain poorly understood (2, 3) .
OCT4, a transcription factor in the POU family of proteins, expressed in both embryonic and adult stem cells, has been associated with the pluripotency, proliferative potential and self-renewal properties observed in embryonic stem cells (ESCs) and germ cells (4) . It is well known that, OCT4, together with three other reprogramming factors, is essential for generating induced pluripotent stem cells (5, 6) . To date, a large body of evidence has demonstrated that OCT4 participates in the initiation and progression of various malignancies, such as germ-cell tumors, bladder cancer and liver cancer (7) (8) (9) (10) . Moreover, expression of OCT4 is required for maintaining the self-renewal and survival of cancer stem-like cells (11, 12) . Nevertheless, relatively little is known about how OCT4 is dysregulated during carcinogenesis.
Non-coding RNAs have recently gained significant attention in delineating the molecular pathogenesis of cancers. Among them, micro RNAs (miRNAs) constitute an evolutionarily conserved class of pleiotropic small RNAs that suppress gene expression posttranscriptionally. Through sequence-specific interactions with the 3′-untranslated regions (UTRs) of cognate mRNA targets, miRNAs usually contribute to translational inhibition or mRNA degradation of large amounts of genes (13) . Interestingly, a recent study showed that, in ESCs, the pluripotency factors OCT4, SOX2 and KLF4 are direct targets of a tumor-suppressive miRNA miR-145 (14) , suggesting that miR-145 might play a critical role in OCT4 dysregulation in cancer (15, 16) . However, the precise relationship between OCT4 and miR-145 in HCC remains largely unknown.
Apart from miRNAs, pseudogenes represent another class of noncoding RNAs, which are defined as genomic elements that resemble real genes. Pseudogenes are previously considered to be biologically inconsequential because they harbor premature stop codons, deletions/insertions and frameshift mutations that abolish their translation into functional proteins. Nevertheless, nucleotide sequences within pseudogenes are well conserved probably due to evolutionary selection pressure, suggesting that they may indeed have an important cellular role (17) . Pseudogenes exhibit tissue-specific expression patterns (18) and are aberrantly activated in malignancies (19) , indicating that pseudogenes may contribute to tumorigenesis, although the mechanisms still remain elusive. Recently, an elegant study conducted by Poliseno et al. (20) showed that pseudogenes could function as competing endogenous RNAs to regulate other RNA transcripts by competing for shared miRNAs. That finding added a new transregulatory dimension to mRNA biology besides the protein-coding function (21) . Interestingly, bioinformatic analysis revealed a higher-than-expected frequency of pseudogenes for ESC-specific genes such as OCT4, Nanog and Stella (22) , suggesting that pseudogenes may coordinate with their parental genes in maintaining the stemness of ESCs/CSCs.
In this study, we report that OCT4 and its pseudogene OCT4-pg4 are aberrantly expressed in HCC and that their expression levels displayed a direct correlation. Moreover, we found that OCT4-pg4 functions as a competing endogenous RNA to protect OCT4 transcript from being inhibited by miR-145, thus playing an oncogenic role in hepatocarcinogenesis. The present work provides the first evidence for the extraordinary crosstalk among miR-145, OCT4 and OCT4-pg4 and sheds new light on the treatment of HCC.
Materials and methods

Patients and specimens
Fresh-frozen and paraffin-embedded primary HCC tissues and corresponding adjacent non-tumorous liver samples were obtained from Chinese patients at Xijing Hospital (Xi'an, China). The use of clinical specimens in this study was approved by the Ethic Committee of Xijing Hospital in Fourth Military Medical University. All cases were reviewed by pathologist and histologically confirmed as HCC. For stratification analysis of survival, the relative expression levels of OCT4-pg4 in HCC (n = 54) and normal liver (n = 10) samples were determined by quantitative real-time PCR (qRT-PCR). The expression data across all samples were calibrated by the median OCT4-pg4 expression level of normal liver tissues. Then, the relative expression values of 54 HCC samples were sorted by descending order and dichotomized by a median split to define high/low groups of OCT4-pg4 expression.
Cell culture
Human embryonic kidney cell line HEK293 and HCC cell line HepG2 were purchased from American Type Culture Collection. SMMC-7721 was obtained from the Type Culture Collection of the Chinese Academy of Sciences. MHCC97-L and MHCC97-H were obtained from Liver Cancer Institute, Zhongshan Hospital. HEK293, HepG2, MHCC97-L and MHCC97-H were grown in Dulbecco's modified Eagle's medium (Gibco BRL) supplemented with 10% fetal bovine serum. SMMC-7721 cells were grown in RPMI-1640
medium (Gibco BRL) supplemented with 10% fetal bovine serum. All cell lines were maintained in a humidified atmosphere at 37°C with 5% CO 2 .
Plasmids, antagomiRs and small interfering RNAs
The full-length OCT4 3′UTR and OCT4-pg4 were generated by PCR amplification from HepG2 cDNA and cloned into pGL3 (Promega, Madison, WI) and pcDNA3.1 (Invitrogen, Carlsbad, CA). The primers used are as follows-OCT4 3′UTR: forward 5′-TGAGGTGCCTGCCCTTCTAG-3′ and reverse 5′-AAGT GATACATGATGTGGGA-3′; OCT4-pg4: forward 5′-CCATGGCGGGACAC CTGGCT-3′ and reverse 5′-GAATGCATGGGAGAGCCCAG-3′. Before cloning, PCR products were run on a 1.2% (w/v) agarose gel to check for size and PCR specificity. Only PCR products of the correct size were excised from the gel and purified using the gel purification kit (Qiagen, Hilden, Germany). Then, the purified PCR products were ligated into the pMD-18T vector (TaKaRa) by TA cloning and sequenced to verify correct insertion of the fragments. For site-specific mutagenesis, DNA sequences were custom synthesized (GenScript Co., Nanjing, China). For miRNA depletion, antagomiRs were purchased from Dharmacon. For gene knockdown, OCT4-pg4-specific siRNA (#SASI_Hs01_00273527; Sigma-Aldrich) and OCT4-specific siRNA (#SASI_Hs01_00193932; Sigma-Aldrich) were purchased, and siRNA against a common region of OCT4 and OCT4-pg4 was custom synthesized (RiboBio Co., Ltd, Guangzhou, China) with the following sequence: 5′-AGCAGCUUGGGCUCGAGAAdTdT-3′.
Western blotting
Total cell lysates were obtained using Triton X-100 lysis buffer supplemented with a protease inhibitor cocktail (Roche, Mannheim, Germany). Twenty microgram total protein was resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane (GE Healthcare, Piscataway, NJ). The membrane was then probed with primary antibodies as follows: OCT4 (POU5F1) (#2876-1, 1:1000; Epitomics) and β-actin (#A1978, 1:4000; Sigma-Aldrich).
RNA extraction and qRT-PCR
Total RNA was isolated by TRIzol (Invitrogen) and treated with RQ1 RNasefree DNase (Promega) to eliminate DNA contamination. Complementary DNA was synthesized from 1 μg of total RNA using miScript Reverse Transcription Kit (Qiagen). Relative expressions of different genes were detected using Roche SYBR Green PCR Kit on the iCycler real-time detection system (Bio-Rad, Hercules, CA). The 2 -∆∆C T method was used in data analysis, with mRNA levels normalized to glyceraldehyde 3-phosphate dehydrogenase and miRNA levels normalized to U6. The normalized level of target gene expression is calculated by using the formula as follows: ΔC T (sample or calibrator) = C T (target gene) − C T (reference gene); ΔΔC T = ΔC T (sample) − ΔC T (calibrator); normalized target gene expression level in sample = 2 -∆∆C T . For detecting miR-145, miScript Primer Assay (#MS00003528; Qiagen) and miScript Universal Primer were used. The primer sequences for other transcript analyzed are as follows-OCT4: forward 5′-GATGGCGTACTGTGGGCCC-3′ and reverse 5′-TGGGACTCCTC CGGGTTTTG-3′; OCT4-pg4: forward 5′-CAGAAACCCTCTTGCAGGCT-3′ and reverse 5′-GAACCACACTCGGACCACAT-3′; glyceraldehyde 3-phosphate dehydrogenase: forward 5′-TGCACCACCAACTGCTTAGC-3′ and reverse 5′-GGCATGGACTGTGGTCATGAG-3′. To make primer sets more specific and avoid PCR artifacts, both OCT4 sense primer and OCT4-pg4 sense primer were designed to carry a polymorphism at the 3′ end, respectively (Supplementary Figure S1 , available at Carcinogenesis Online). The specificity of these qPCR primers was experimentally verified by sequencing the amplified products obtained in the qPCR assay (Supplementary Table S3 , available at Carcinogenesis Online).
Sequencing analysis
The homology analysis of OCT4 transcript and its pseudogenes was carried out by using the BioEdit software. The universal primer set (forward 5′-TTGCCAAGCTCCTGAAGCAG-3′ and reverse 5′-GCAGATGGTCG TTTGGCTGA-3′) was designed based on the most homologous region that made the primers perfectly complementary to the OCT4 mRNA and all six pseudogenes (Supplementary Table S6 , available at Carcinogenesis Online). RT-PCR assay using the universal primer set was performed for all samples. PCR products were run on a 1.5% (w/v) agarose gel and the positive electrophoretic bands were purified using the gel purification kit (Qiagen). Then the purified PCR products were ligated into the pMD-18T vector (TaKaRa) by TA cloning and sequenced via automated sequencing. The sequencing results were analyzed by using the Nucleotide BLAST program and the BioEdit software.
Luciferase reporter assay
Cells of 60-90% confluence in 48-well plates were transfected using Lipofectamine 2000 (Invitrogen). One hundred nanograms of firefly luciferase reporter gene construct and 5 ng of the pRL-TK Renilla luciferase construct (for normalization) were cotransfected per well. Cell extracts were prepared 48 h after transfection, and the luciferase activity was measured using the DualLuciferase Reporter Assay System (Promega). The experiment was carried out in triplicate wells for at least three times.
Cell viability assay
Cells, seeded in 96-well plates, were stained at the indicated time points with 100 μl sterile 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide dye (0.5 mg/ml; Sigma) for 4 h at 37°C. The supernatant was then aspirated and 150 μl dimethyl sulfoxide was added into each well. The intensity of formazan formed was measured at 570 nm using Victor Wallac microplate reader (PerkinElmer, Waltham, MA). The experiment was carried out in quintuplicate wells for at least three times.
Colony formation assays
Cells were seeded at the density of 1 × 10 3 cells/well in 12-well plates and cultured for 10 days. Following paraformaldehyde fixation and crystal violet staining, the cultures were photographed using GelDoc System (Bio-Rad) and stained cell colonies were counted by Quantity One software (Bio-Rad). The experiment was carried out in triplicate wells for at least three times.
Xenograft tumor model
Six-week-old BALB/c nude mice were purchased from the Model Animal Research Center of Nanjing University. All animal procedures were performed in accordance to the protocols approved by the Institutional Animal Care and Use Committee at the Fourth Military Medical University. For xenograft models, 5 × 10 6 HepG2 cells stably expressing OCT4-pg4 or transfected with 2′-O-Me-modified si-OCT4-pg4 were injected subcutaneously in the right flank of BALB/c nude mice (five mice per group). Tumor growth was monitored every 5 days for a total period of 30 days. Tumor volumes were calculated by using the following formula:
, where a is the largest diameter and b is the perpendicular diameter.
Immunohistochemistry
Immunohistochemical staining was performed on formalin-fixed paraffinembedded tissue sections. A rabbit monoclonal antibody against OCT4 (#2876-1; Epitomics) was used and isotype-matched rabbit immunoglobulin G antibody served as a negative control. Chromogen development was performed with ultraView Universal DAB detection kit (Ventana Medical Systems). The percentage of positive cells and staining intensity were multiplied to produce a weighted score for each case.
Statistical analysis
Statistical analysis was performed using SPSS 11.0 for Windows. All data were presented as mean ± SD. Disease-free and overall survival was analyzed with the Kaplan-Meier method and the statistical probability (P-value) was generated by log-rank test. The significance of associations between OCT4 and OCT4-pg4 expression values was judged via a test statistic based on Pearson product-moment correlation coefficient. Two-tailed Student's t-test was used to evaluate the statistical significance of differences between two groups of data in luciferase assay, qRT-PCR and cell growth assay. Differences were considered significant when P < 0.05 (*), P < 0.01 (**) or P < 0.001 (***).
Results
OCT4 is aberrantly expressed in HCC and directly targeted by miR-145
To investigate the expression of OCT4 protein in HCC, we performed immunohistochemical staining in 54 HCC tissues and 10 normal liver tissues. Among the 54 HCC tissues, 21 (38.9%) cases were positive for OCT4; however, none of the normal liver tissues exhibited obvious expression of OCT4 ( Figure 1A) . To study the clinical significance of OCT4 accumulation in HCC progression, we examined the correlation between OCT4 level and disease stage. Results revealed that the expression levels of OCT4 were remarkably increased during HCC progression, indicating that upregulation of OCT4 is clearly related to HCC stage ( Figure 1A and B) .
It is known that miR-145 can regulate OCT4 expression and repress pluripotency in human ESCs (14) . To test whether miR-145 plays a functional role in suppressing OCT4 during liver carcinogenesis, we performed a reporter gene assay in HCC cells. Results showed that miR-145 significantly repressed the luciferase activity of reporter vector harboring wild-type 3′UTR of OCT4, whereas mutation of the putative miR-145 binding site in OCT4 3′UTR abrogated the inhibitory effect of miR-145 ( Figure 1C ). Western blotting analyses further confirmed that the OCT4 protein level was markedly decreased upon miR-145 transfection ( Figure 1D ). However, miR-145 had no effect on the mRNA level of OCT4 as determined by qRT-PCR ( Figure 1E ), suggesting that miR-145 regulates OCT4 expression via translational inhibition in HCC cells.
OCT4-pg4 is positively correlated with OCT4 in expression level and can be targeted by miR-145 in HCC
Given that OCT4 is a direct target of miR-145, we speculated that there would be an inverse correlation between the expression levels of miR-145 and OCT4 in HCC. However, no obvious correlation (r = −0.0671, P = 0.6299) between miR-145 and OCT4 protein levels was observed (Figure 2A ), indicating that other mechanisms might be involved in regulating OCT4 expression. The human OCT4 has six pseudogenes, of which OCT4-pg1, OCT4-pg3 and OCT4-pg4 were found to be transcribed in somatic cancers (23, 24) . To investigate the expression of OCT4 pseudogenes in HCC, we performed DNA sequencing analysis following RT-PCR. Results showed that OCT4-pg4 represents the majority of OCT4 pseudogenes and is expressed along with OCT4 in HCC cells (Supplementary Table S1 , available at Carcinogenesis Online). Furthermore, we found a positive correlation between OCT4 and OCT4-pg4 levels in HCC clinical samples (r = 0.8391, P < 0.0001) ( Figure 2B ) and in several HCC cell lines ( Figure 2C ), suggesting that OCT4-pg4 may play a functional role in OCT4 upregulation.
OCT4-pg4 (POU5F1P4) is a processed pseudogene located at 1q22. It is highly homologous to the coding sequence of OCT4 (POU5F1), with only 33 mismatches throughout the RNA body; however, a frameshift mutation near the AUG initiator codon impedes the translation of OCT4-pg4 transcript (Supplementary Table S2 , available at Carcinogenesis Online). Although OCT4-pg4 lacks the OCT4 3′UTR, which can be targeted by miR-145, the sequence variations of it coincidently contribute to the formation of a novel tandem seed matches for miR-145 ( Figure 2D) . Strikingly, the free energy predicted for hybridization with OCT4-pg4 and miR-145 at these sites is Δ = −23.30 and −22.30 kcal/mol, respectively ( Figure 2D ), indicating that OCT4-pg4 is a strong candidate target for miR-145. Then, we cloned the full-length OCT4-pg4 downstream of the luciferase gene. Reporter assays revealed that the luciferase activity was reduced by ~80% upon miR-145 transfection, and this effect was eliminated through mutation of the putative miR-145 binding sites in OCT4-pg4 ( Figure 2E ). Further qRT-PCR analysis demonstrated that overexpression of miR-145 has only a slight effect on the mRNA stability of OCT4-pg4 ( Figure 2F ). Overall, these data raised the possibility that OCT4-pg4 might function as a miRNA decoy for miR-145 in HCC.
OCT4-pg4 functions as a miRNA decoy for miR-145 to upregulate OCT4 in HCC
To evaluate the role of OCT4-pg4 in regulating OCT4 expression, we performed reporter assays using the reporter construct harboring wild-type 3′UTR of OCT4. We found that OCT4-pg4 overexpression remarkably increased the luciferase activity in both HEK293 and HepG2 cells, and the inhibitory effect of miR-145 on OCT4 was reversed upon OCT4-pg4 transfection ( Figure 3A) . However, mutation of the miR-145 binding sites in OCT4-pg4 entirely abrogated these effects (Figure 3B ), suggesting that OCT4-pg4 could be a competitive antagonist of miR-145 in HCC cells.
Next, we employed RNAi-mediated knockdown to study the lossof-function phenotypes of OCT4-pg4. Gene-specific siRNAs were designed against the variable regions of OCT4-pg4 to distinguish it from OCT4 (Supplementary Table S2 , available at Carcinogenesis Online). The qRT-PCR analysis revealed that transfection of siRNA against OCT4-pg4 reduced OCT4-pg4 levels to <20% but had no effect on OCT4 levels, whereas overexpression of siRNA against a common region of OCT4-pg4 and OCT4 remarkably inhibited both genes simultaneously ( Figure 3C ). In addition, the siRNA specificity was further confirmed via sequencing analysis following the qPCR assay (Supplementary Table S4 , available at Carcinogenesis Online). Reporter assays in HCC cell lines showed that OCT4-pg4 knockdown significantly repressed the luciferase activity of reporter vector harboring wild-type 3′UTR of OCT4 ( Figure 3D) . Notably, this effect could be completely abolished by antagomiR-mediated miR-145 inhibition ( Figure 3D ), suggesting that OCT4 repression mediated by OCT4-pg4 knockdown was largely dependent on endogenous miR-145 expression in HCC. Western blotting analyses confirmed that OCT4 protein level was decreased upon OCT4-pg4 knockdown and could be rescued by transfection of antagomiR-145 ( Figure 3E) . Furthermore, we found that OCT4-pg4 knockdown had no effect on the luciferase activity of reporter vector harboring mutated-type 3′UTR of OCT4 ( Figure 3F ). Taken together, above data demonstrated that pseudogene OCT4-pg4 functions as a miRNA decoy to protect OCT4 from being inhibited by miR-145 in HCC.
To test whether OCT4-pg4 knockdown could enhance the efficiency of miR-145-mediated OCT4 inhibition, we performed reporter assays in HCC cell lines. The reporter vector containing wild-type 3′UTR of OCT4 was cotransfected with different concentrations of miR-145 mimics. We found that transfection of 100 nM miR-145 mimics reduced the luciferase activity by ~40%, whereas transfection of 10 nM miR-145 mimics had only a negligible effect ( Figure 3G) . However, upon OCT4-pg4 knockdown, miR-145 treatment at the concentration of 10 nM reduced the luciferase activity to a level comparable with that of 100 nM ( Figure 3G) , strongly supporting the notion that OCT4-pg4 antagonizes miR-145 function in HCC.
OCT-pg4 promotes cell proliferation and colony formation of HCC cells
To explore the biological role of OCT4-pg4 in hepatocarcinogenesis, we performed 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide assays following gene-specific knockdown of OCT4-pg4 and OCT4. Results showed that OCT4-pg4 knockdown significantly inhibited cell proliferation of HepG2 cells ( Figure 4A ). Besides, we found that simultaneous knockdown of OCT4-pg4 and OCT4 showed the strongest effect ( Figure 4A ), indicating that OCT4 and its pseudogene may have additive roles for growth promotion. Moreover, these observations were further confirmed by a colony formation assay ( Figure 4B ). Since SMMC-7721 HCC cells exhibit low levels of OCT4-pg4 and OCT4 (Figure 2C ), we used it for gain-of-function study. Stable transfection of wild-type OCT4-pg4 in SMMC-7721 cells resulted in remarkable upregulation of OCT4 proteins (Figure 4C) , accelerated cell proliferation rate ( Figure 4D ) and increased colony number ( Figure 4E ), suggesting that OCT4-pg4 exerts an oncogenic role during hepatocarcinogenesis.
OCT-pg4 overexpression enhances tumorigenicity of HCC cells and is associated with poorer prognosis of HCC patients
To confirm the in vitro findings, we used a nude mouse xenograft model to detect the HCC-promoting effect of OCT4-pg4. HepG2 cells stably expressing OCT4-pg4 or cells treated with siRNA against OCT4-pg4 were subcutaneously injected into the posterior flanks of nude mice. Analysis of tumor growth curves revealed that OCT4-pg4-overexpressing cells grew faster than control cells, whereas OCT-pg4 knockdown significantly attenuated tumorigenicity of HepG2 cells ( Figure 5A and B) . To evaluate whether the expression level of OCT4-pg4 correlates with survival of HCC patients, we investigated a cohort of 54 HCC patients. Kaplan-Meier analysis revealed that high OCT4-pg4 level in HCC tissues is significantly correlated with the markedly reduced disease-free survival and overall survival of HCC patients ( Figure 5C ), suggesting the important roles of OCT4-pg4 in pathogenesis of HCC and prognosis of HCC patients.
Discussion
Like other solid tumors, HCCs appear to be sustained by a minority population of CSCs. Dedifferentiated hepatocytes, hepatic oval cells and bone marrow cells are the three major types of liver stem cells (25) . Recent studies showed that liver CSCs could be enriched via different cell surface markers, such as CD13, CD24, CD44, CD90, CD133, EpCAM (CD326) and OV6. Liver CSCs could also be identified through functional assays, e.g. selecting cells with high aldehyde dehydrogenase activity or isolating the side population cells by Hoechst dye staining (26) . Moreover, accumulating evidence has demonstrated that several signaling pathways that are critical for inducing the HCC stemness are dysregulated during hepatocarcinogenesis, such as Wnt/β-catenin, transforming growth factor-beta and IL-6/STAT3 pathways (27, 28) . However, the molecular genetics and the mechanisms responsible for the highly aggressive clinical picture of HCC still remain poorly understood.
In this study, we demonstrate that OCT4, a pluripotency sustaining factor in embryonic stem cells, is aberrantly expressed in advanced HCC. OCT4, also known as POU5F1, is initially transcribed as a maternal transcription factor in the oocyte but remains active in embryos throughout the preimplantation period (29) . OCT4 expression is associated with an undifferentiated phenotype (30) , and numerous studies point to the fact that OCT4 is expressed in various types of human cancer but not in normal somatic tissues (31) (32) (33) . Nevertheless, some studies aroused controversy with the finding that OCT4 expression is absent in multiple tumor cell lines (34, 35) . Here, our data showed that OCT4 protein is not expressed in normal liver tissues and is nearly absent in early stage HCCs (stage I), whereas in late-stage HCCs (stage II or stage III), OCT4 protein is overexpressed at a high frequency ( Figure 1A and B) . This finding, in line with previous reports (7, 8) , supports the notion that OCT4 expression is dysregulated in HCC. Our functional study further revealed that knockdown of OCT4 in HCC cells resulted in reduced cell proliferation and colony-forming ability ( Figure 4A and B) , suggesting an oncogenic role for OCT4 in hepatocarcinogenesis. In addition, Wang et al. (36) demonstrated that OCT4 could mediate chemotherapeutic drug resistance in HCC through a potential OCT4-AKT-ATP-binding cassette G 2 pathway. Given the critical role of OCT4 in maintaining the stemness of stem cells, we argue that the OCT4-positive HCC cells, which are characterized by chemoresistance and proliferative potential, are probably derived from liver CSCs.
OCT4 expression must be closely regulated. The precise level of OCT4 governs three distinct fates of ESCs. A <2-fold increase of OCT4 protein turns ESCs into primitive endoderm and mesoderm, whereas repression of OCT4 induces loss of pluripotency and dedifferentiation to trophectoderm (37) . In ESCs, OCT4 can be transcriptionally activated by itself (38) and negatively regulated by miR-145 (14) . miR-145 is a well-known tumor-suppressive miRNA, which is often downregulated in multiple types of malignancy, including HCC (39) (40) (41) (42) . Therefore, it seems plausible to reason that OCT4 overexpression in cancer is caused by miR-145 downregulation. However, we did not observe a reverse correlation between miR-145 and OCT4 levels in HCCs (Figure 2A ). On the other hand, our study demonstrated that a non-coding RNA expressed from the OCT4 pseudogene OCT4-pg4 was able to regulate the corresponding OCT4 protein level in HCC by acting as a miRNA decoy for miR-145 ( Figure 5D ).
In mouse oocytes, processed pseudogenes could be processed into endogenous small interfering RNAs that inhibit the expression of cognate genes through conventional RNA interference (43) . However, endogenous small interfering RNA pathway has yet to be identified in human somatic cells (44) . Besides, it is notable that only a small percentage of pseudogenes undergo antisense transcription, whereas all transcribed pseudogenes are theoretically capable of competing with cognate mRNAs for miRNA binding. Five years ago, Ebert et al. (45) introduced artificial miRNA decoys termed 'miRNA sponges' as a means to create loss-of-function phenotypes for miRNAs in mammalian cells. Given the efficacy of stably integrated miRNA sponges to inhibit miRNA seed families, it seems reasonable that endogenous non-coding RNAs might have evolved to be able to sequence-specifically sequester miRNAs. The first such natural miRNA sponge was discovered in plants, in which the trehalose-6-phosphate synthase RNAs can attenuate the miR-399-mediated stress response (46) . More recently, Poliseno et al. (20) found that the mammalian pseudogene PTENP1 could function as a competing endogenous RNA to regulate PTEN expression by competing for shared miRNAs. The 3′UTR of PTENP1 is highly homologous to that of PTEN, thus playing a critical role in sequestering miRNAs. In our study, a lack of 3′UTR in the pseudogene OCT4-pg4 was observed, indicating that OCT4-pg4 might have lost its ability to function as a miRNA decoy. However, as miRNA binding sites are located in open reading frame sequences as well (47) , the entire transcript of pseudogenes may possess decoy function. Our subsequent analysis showed that the sequence variations of OCT4-pg4 coincidently contribute to the formation of a novel tandem seed matches for miR-145. Furthermore, OCT4-pg4 displayed a much higher affinity for miR-145 compared with OCT4 transcript, strongly supporting the notion that OCT4-pg4 functions as a miRNA decoy for miR-145 in HCC. Interestingly, pseudogene OCT4-pg4 is located at 1q22, a chromosomal region frequently amplified in HCC (48) , suggesting that the aberrant expression of OCT4-pg4 is probably due to gene amplification. Bioinformatic analysis revealed that OCT4-pg4 sits in the intron of ASH1L, a large gene spanning over 220 kb of the human genome. Therefore, the OCT4-pg4 expression is likely to be influenced by the transcription of its host gene. However, the transcriptional orientations of these two genes are just opposite, with OCT4-pg4 on the sense strand and ASH1L on the antisense strand (Supplementary Figure S2 , available at Carcinogenesis Online), strongly suggesting that OCT4-pg4 probably has its own promoter and transcribes independently. It is also noteworthy that ASH1L is an activating histone methyltransferase upregulated in HCC (49), so it is still possible that the transcription of OCT4-pg4 would be influenced by the transacting function of ASH1L. Overall, the discovery of pseudogene transcripts that block miRNA activity has revealed a new layer of posttranscriptional regulation with many potential biological roles.
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